Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy

Onkologie

Volumn 25, Issue 1, 2002, Pages 32-39

  Bokemeyer, C ^a   Honecker, F ^a   Wedding, U ^b   Spaeth Schwalbe, E ^c   Lipp, H P ^a   Kolb, G ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Vivantes Klinikum Spandau   (Germany)

^d ST BONIFATIUS HOSPITAL   (Germany)

Author keywords

Chemotherapy; Elderly patients; Hematopoietic growth factors

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PIRARUBICIN; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIESIS; HUMAN; INFECTION COMPLICATION; LYMPHOMA; NEUTROPENIA; NEUTROPHIL; QUALITY OF LIFE; SENESCENCE; SHORT SURVEY;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; NEOPLASMS; NEUTROPENIA; PREDNISONE; VINCRISTINE;

EID: 0036119062     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055200     Document Type: Short Survey

References (54)

1. Management of cancer in the older person: A practical approach
2. Aging and pharmacology
3. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
4. Ageing and the neutrophil: No appetite for killing?
5. Bone marrow CD34 cells generate fewer T cells in vitro with increasing age and following chemotherapy
6. Cancer chemotherapy in the elderly
7. Aging and hemopoiesis
8. Anämie bei alten menschen - Ein spezielles diagnostisches und therapeutisches problem?
9. Numbers and functions of transplantable primitive immunohematopoietic stem cells. Effects of age
10. Altern des hämatopoetischen systems
11. Hematopoiesis and cytokines
12. Recombinant hemopoi-etic growth factors: Comparative hemopoietic response in younger and older subjects
13. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance
14. A predictive model for aggressive non-Hodgkin's lymphoma
15. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
16. Management of acute myeloid leukemia in elderly patients
17. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis
18. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen
19. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia
20. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
21. Einsatz hämatopoetischer wachstumsfaktoren in der therapie hämatologischer und onkologischer krankheiten
22. Hematopoietic myeloid growth factors in the treatment of acute myelogenous leukaemia: Players on or off stage?
23. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
24. General guidelines for the management of older patients with cancer. NCCN Proceeding
25. Patients aged > 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy
26. Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey
27. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
28. The association of intraoperative factors with the development of postoperative delirium
29. Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life
30. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study
31. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models
32. Correction of cancer anemia - Impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy
33. Erythropoietin in radiation oncology - A review. 1st International Conference, Freiburg i.Br., June 11-12, 1999
34. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
35. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials
36. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia
37. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
38. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
39. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized trial
40. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
41. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
42. Hemopoietic reserve in the older cancer patient: Clinical and economic considerations
43. Erythropoietin reduces anemia and transfusions - A randomized trial with or without erythropoietin during chemotherapy
44. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the eastern cooperative oncology group (E1490)
45. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
46. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group B
47. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
48. A placebo-controlled study of recombinant human granulocyte-macrophage stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
49. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly partients with aggressive non-Hodgkin's lymphoma
50. CHOP is the standard regimen in patients >70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
51. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years
52. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
53. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy
54. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age